With Breanne Deppisch and Joanie Greve. THE BIG IDEA: The Trump administration doesn’t care about free and fair elections, except when it does. In March, White House press secretary Sarah Huckabee Sanders was asked whether President Trump agreed with John McCain that Vladimir Putin’s reelection in Russia was a “sham.” “We're focused on our elections. We don't get to dictate how other countries operate,” Sanders replied. “What we do know is Putin has been elected in their country, and that's not something that we can dictate to them, how they operate. We can only focus on the freeness and the fairness of our elections.” Trump had ignored specific warnings from his own national security team — including a section in his briefing materials that said “DO NOT CONGRATULATE” in all caps — when he congratulated Putin for securing six more years. Yet, on Monday, Trump issued a strongly worded statement condemning the … [Read more...] about The Daily 202: A tale of two elections
Doctoral letter of intent sample
A group of cancer doctors focused on bringing down the cost of treatments by testing whether lower - and cheaper - doses are effective thought they had found a prime candidate in a blood cancer drug called Imbruvica that typically costs $148,000 a year.The science behind Imbruvica suggested that it could work at lower doses, and early clinical evidence indicated that patients with chronic lymphocytic leukemia might do just as well on one or two pills a day after completing an initial round of treatment at three pills per day.The researchers at the Value in Cancer Care Consortium, a nonprofit focused on cutting treatment costs for some of the most expensive drugs, set out to test whether the lower dose was just as effective - and could save patients money.Then they learned of a new pricing strategy by Janssen and Pharmacyclics, the companies that sell Imbruvica through a partnership. Within the next three months, the companies will stop making the original 140-milligram capsule, a … [Read more...] about Science hinted that cancer patients could take less of a $148,000-a-year drug. Its maker tripled the price of a pill.